自體免疫疾病相關共同研究及授權契約:2016～2025年

Autoimmune Collaboration and Licensing Deals 2016-2025

出版日期: 2025年10月01日 | 出版商:

Current Partnering | 英文 500+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告全面深入分析了全球領先的生物製藥公司簽署的自身免疫性疾病合作與許可協議，並提供前所未有的資訊取得管道。

本報告詳細介紹了2016年至2025年間達成的943項自體免疫疾病協議。

目標自體免疫疾病：多發性硬化症、不寧腿症候群、皮膚炎、濕疹、掉髮、乾癬、乳糜瀉、發炎性腸道疾病、克隆氏症、潰瘍性結腸炎、腎絲球腎炎、子宮內膜異位症、免疫性血小板減少性紫斑症、嗜中性白血球減少症、移植物抗毛疾病、手術性疾病、手術性糖尿病系統僵直性脊椎炎、幼年特發性關節炎、乾癬性關節炎、類風濕性關節炎、葡萄膜炎、發作性睡病、慢性阻塞性肺病、特發性肺纖維化、結節病、梅尼爾氏症和其他自體免疫疾病。

主要的優點

2016 年以來的合約趨勢
自體免疫領域的合作與授權協議
透過基準分析確定市場價值
財務條款（預付款、里程碑付款、特許權使用費）
按公司、治療領域和技術類型分類的合約目錄
主要合約金額
最活躍的交易撮合者
查看每份合約的資產描述和條款
存取合約文件 - 深入了解合約結構
盡職調查 - 評估擬議合約條款是否適合您的合作夥伴
節省數百小時的研究時間

合約分析可協助您對以下內容進行盡職調查：

具體授予或選擇哪些權利？
合約實際授予合作夥伴哪些權利？
授予了哪些獨家經營權？
合約的付款結構是什麼？
收入和付款如何審計？
合約期限是多久？
合約的關鍵條款是如何定義的？
智慧財產權（IPR）將如何處理，所有權歸誰？
誰負責商業化？
誰負責開發、供應和生產？
如何管理保密性和結果揭露？
如何解決爭議？
在什麼情況下可以終止合約？
如果公司所有權發生變更，合約會如何處理？
關於轉授權和分包，雙方約定了哪些條款？
公司通常會包含哪些 "範本條款" ？
依合約當事人及合約類型而有所不同的 "範本條款" 有哪些？
根據合約法，公司要求適用哪一方（法院）的管轄法律？

Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of autoimmune dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in autoimmune dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the autoimmune field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in autoimmune dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of autoimmune deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of autoimmune deals listed by theraeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in autoimmune deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Autoimmune Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2016
Browse autoimmune collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Autoimmune Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of autoimmune trends and structure of deals entered into by leading biopharma companies worldwide.

Autoimmune Collaboration and Licensing Deals includes:

Trends in autoimmune dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of autoimmune deal records covering pharmaceutical and biotechnology
The leading autoimmune deals by value
Most active autoimmune licensing dealmakers

In Autoimmune Collaboration and Licensing Deals, the available deals are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Autoimmune Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?